Global prevalence of CLDN18.2 in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Biomarker analysis of two zolbetuximab phase 3 studies (SPOTLIGHT and GLOW)

被引：0
|
作者：
Shitara, Kohei
Xu, Rui-Hua
Moran, Diarmuid Martin
Guerrero, Abraham
Li, Ran
Pavese, Janet
Matsangou, Maria
Bhattacharya, Pranob P.
Ajani, Jaffer A.
Shah, Manish A.
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[2] Sun Yat Sen Univ, Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Astellas Pharma Global Dev Inc, Northbrook, IL USA
[4] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Weill Cornell Med Coll, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4035
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
    Bang, Y-J.
    Shen, L.
    Kang, Y-K.
    Chao, Y.
    Soo, H. H. F.
    Sunpaweravong, P.
    Moran, D.
    Guerrero, A.
    Li, R.
    Pavese, J.
    Matsangou, M.
    Bhattacharya, P.
    Shitara, K.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2023, 34 : S1527 - S1528
  • [2] First-line (1L) zolbetuximab plus chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT plus GLOW
    Kang, Y-K.
    Shah, M. A.
    Shitara, K.
    Ajani, J. A.
    Lordick, F.
    Van Cutsem, E.
    Ilson, D. H.
    Klempner, S. J.
    Yamaguchi, K.
    Nakajima, T.
    Cao, Y. J.
    Li, R.
    Moran, D.
    Pophale, R. R.
    Ranganath, R.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S895 - S895
  • [3] Zolbetuximab + CAPOX in 1L Claudin-18.2+(CLDN18.2+)/HER2-Locally Advanced (LA) Unresectable or Metastatic Gastric or Gastroesophageal Junction (mG/GEJ) Adenocarcinoma: Primary Phase 3 Results From GLOW
    Lordick, F.
    Xu, R. -H
    Shitara, K.
    Ajani, J. A.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Van Cutsem, E.
    Gallego Plazas, J.
    Huang, J.
    Shen, L.
    Oh, S. C.
    Sunpaweravong, P.
    Hoo, Soo H. F.
    Turk, H. M.
    Park, J. W.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Shah, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 116 - 117
  • [4] Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab plus chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.
    Shitara, Kohei
    Pophale, Rupesh
    Matsangou, Maria
    Park, Jung Wook
    Oh, Mok
    Bhattacharya, Pranob P.
    Ranganath, Radhika
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 372 - 372
  • [5] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER22locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
    Xu, Rui-hua
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Lordick, Florian
    Van Cutsem, Eric
    Plazas, Javier Gallego
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Hoo, Hwoei Fen Soo
    Turk, Haci M.
    Park, Jung Wook
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [6] Zolbetuximab + CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced (LA) or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary phase 3 results from GLOW.
    Xu, Rui-Hua
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Lordick, Florian
    Van Cutsem, Eric
    Gallego Plazas, Javier
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Soo Hoo, Hwoei Fen
    Turk, Haci M.
    Park, Jung Wook
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Shah, Manish A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 405736 - 405736
  • [7] SYMPTOM BURDEN AND HEALTHCARE RESOURCE USE IN CLAUDIN 18.2+(CLDN18.2+), HER2-PATIENTS WITH LOCALLY ADVANCED (LA) UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (MG/GEJ) ADENOCARCINOMA
    Sewastjanow-Silva, M.
    Rogers, J. E.
    Waters, R. E.
    Rosa, Vicentini E.
    Totev, T.
    Wu, Eq
    Yang, H.
    Chang, L.
    Oh, M.
    Ajani, J.
    VALUE IN HEALTH, 2024, 27 (06) : S401 - S401
  • [8] Zolbetuximab+mFOLFOX6 as first-line (1L) treatment for patients (pts) withclaudin-18.2+(CLDN18.2+) / HER22 locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study
    Shitara, Kohei
    Lordick, Florian
    Bang, Yung-Jue
    Enzinger, Peter C.
    Ilson, David H.
    Shah, Manish A.
    Van Cutsem, Eric
    Xu, Rui-hua
    Aprile, Giuseppe
    Xu, Jianming
    Chao, Joseph
    Pazo-Cid, Roberto
    Kang, Yoon-Koo
    Yang, Jianning
    Moran, Diarmuid Martin
    Bhattacharya, Pranob P.
    Arozullah, Ahsan
    Park, Jung Wook
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : LBA292 - LBA292
  • [9] Zolbetuximab+mFOLFOX6 as First-Line (1L) treatment for patients (Pts) with Claudin-18.2+(CLDN18.2+) / HER2-Locally Advanced (LA) unresectable or metastatic Gastric or Gastroesophageal Junction (mG/GEJ) adenocarcinoma: primary results from Phase 3 SPOTLIGHT Study
    Lordick, F.
    Shitara, K.
    Bang, Y. -J
    Enzinger, P.
    Ilson, D.
    Shah, M. A.
    Van Cutsem, E.
    Xu, R. -H
    Aprile, G.
    Xu, J.
    Chao, J.
    Pazo-Cid, R.
    Kang, Y. K.
    Yang, J.
    Moran, D.
    Bhattacharya, P.
    Arozullah, A.
    Park, J. W.
    Ajani, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 115 - 116
  • [10] Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
    Shah, Manish A.
    Shitara, Kohei
    Ajani, Jaffer A.
    Bang, Yung-Jue
    Enzinger, Peter
    Ilson, David
    Lordick, Florian
    Van Cutsem, Eric
    Plazas, Javier Gallego
    Huang, Jing
    Shen, Lin
    Oh, Sang Cheul
    Sunpaweravong, Patrapim
    Soo Hoo, Hwoei Fen
    Turk, Haci Mehmet
    Oh, Mok
    Park, Jung Wook
    Moran, Diarmuid
    Bhattacharya, Pranob
    Arozullah, Ahsan
    Xu, Rui-Hua
    NATURE MEDICINE, 2023, 29 (08) : 2133 - +
12345